Edition:
United States

Wilex AG (WL6G.F)

WL6G.F on Frankfurt Stock Exchange

2.60EUR
24 Apr 2017
Change (% chg)

€0.07 (+2.89%)
Prev Close
€2.53
Open
€2.60
Day's High
€2.60
Day's Low
€2.60
Volume
0
Avg. Vol
11,198
52-wk High
€3.19
52-wk Low
€1.38

Latest Key Developments (Source: Significant Developments)

Wilex says plans rights issue using authorised capital
Monday, 24 Apr 2017 04:02am EDT 

April 24 (Reuters) - Wilex AG ::Plans rights issue using authorised capital.To increase company's share capital using authorized capital from 12,927,564.00 euros by up to 2,040,816.00 euros to up to 14,968,380.00 euros ($16.27 million).To increase share capital by issuing up to 2,040,816 new shares with a notional value of 1.00 euro each and full entitlement to dividends effective 1 December 2016 in return for cash contributions.  Full Article

Wilex Q1 net loss widens to 2.0 million euros
Wednesday, 12 Apr 2017 01:19am EDT 

Wilex AG : Outlook for 2017: increase in sales revenue forecast; investments in proprietary atac pipeline . Financial guidance remains unchanged compared to that provided on 30 March 2017 . In first three months of fiscal year 2017, Wilex Group generated sales revenue and income totaling 0.6 million euros (previous year: 1.0 million euros) . Net loss for first three months of fiscal year increased to 2.0 million euros, as planned (previous year: 1.1 million euros) .Based on current planning and assuming planned corporate actions are carried out, company's financing is secured until end of Q2 of 2018.  Full Article

Wilex posts FY net loss of 6.4 million euros
Thursday, 30 Mar 2017 01:00am EDT 

Wilex AG : Financials in line with guidance . Outlook for 2017: increase in sales revenue forecast; higher investments in proprietary atac pipeline . Generated sales revenue and other income totaling 2.7 million euros ($2.90 million) in fiscal year 2016 (previous year: 3.9 million euros) . FY net loss for year was 6.4 million euros (previous year: 6.6 million euros) . Wilex group's FY operating result was -6.4 million euros in 2016 fiscal year (previous year: -6.5 million euros) . Expects to generate between 4.0 million euros and 6.0 million euros in sales revenue and other income (2016: 2.7 million euros) for 2017 fiscal year .Earnings before interest and taxes (EBIT) for 2017 fiscal year are projected to be between -6.0 million euros and -10.0 million euros (2016: -6.4 million euros).  Full Article

Wilex subsidiary Heidelberg Pharma and Nordic Nanovector enter into collaboration
Wednesday, 26 Oct 2016 01:00am EDT 

Wilex AG : Subsidiary Heidelberg Pharma and Nordic Nanovector enter into collaboration to develop novel antibody drug conjugates (ADC) .Collaboration aims at developing novel antibody drug conjugates (ADCS) to treat leukemias.  Full Article

Wilex 9-month net loss widens to 4.1 mln euros
Thursday, 13 Oct 2016 01:19am EDT 

Wilex AG : In first 9-month generated sales revenue and income totaling 2.3 million euros ($2.58 million), down 21 pct compared to previous year (2.9 million euros) . At 4.1 million euros, Wilex group's net loss for first nine months of financial year increased year-on-year from 3.5 million euros as a result of lower sales revenue . There is no change to guidance for Wilex Group for current financial year issued at end of march 2016 .Based on current planning company's financing has been secured into Q2 of 2017.  Full Article

Wilex H1 net loss up 26 pct at EUR 2.4 mln
Thursday, 14 Jul 2016 01:10am EDT 

Wilex AG : H1 sales revenue and income totalling 1.9 million euros ($2.11 million), down 17 percent on previous year (2.3 million euros) . Net loss for first half of year rose by 26 percent to 2.4 million euros from 1.9 million euros .There is no change to guidance for Wilex Group for current financial year issued at end of march 2016.  Full Article

Wilex granted a patent in Europe for the chemical synthesis of dihydroxyisoleucine
Tuesday, 28 Jun 2016 01:30am EDT 

Wilex AG : European patent office grants patent for chemical synthetic building block dihydroxyisoleucine for production of Amanitin .Patent has a term until 2033.  Full Article

Wilex unit Heidelberg Pharma enters into partnership with Canadian APC
Tuesday, 14 Jun 2016 09:00am EDT 

Wilex AG :Heidelberg Pharma GmbH, a subsidiary of Wilex AG, entered into a partnership with Canadian APC to create a new generation of antibody-drug conjugates (ADCs).  Full Article

Wilex appoints Andreas Pahl as new Head of Research And Development
Thursday, 2 Jun 2016 07:50am EDT 

Wilex AG : Announces change on the executive management board .Andreas Pahl has been appointed to company's executive management board to serve as new Head of Research and Development.  Full Article

Wilex plans rights issue using authorised capital
Monday, 4 Apr 2016 04:55am EDT 

Wilex AG:Plans rights issue using authorised capital.To increase company's share capital using authorised capital from 10,679,292.00 euros by up to 2,248,272.00 euros to up to 12,927,564.00 euros by issuing up to 2,248,272 new no-par value shares.Subscription price is fixed at 1.84 euro.New shares will be offered to shareholders at a 19:4 ratio by means of an indirect subscription right by ODDO SEYDLER BANK AG.Expected gross proceeds from rights issue of 4.13 million euros.Subscription period will begin on April 8, 2016 and will end on April 22, 2016.Plans to use proceeds to finance further development of platform technology for Antibody-Targeted Amanitin Conjugates (ATAC), to build own ATAC product pipeline against cancer diseases and to expand customer-specific research business.  Full Article

More From Around the Web

BRIEF-Wilex Q1 net loss widens to 2.0 million euros

* Outlook for 2017: increase in sales revenue forecast; investments in proprietary atac pipeline